Skip to main contentSkip to navigationSkip to search
Curasight
  DKK  % |
Curasight

Curasight presents at the SEB Nordic Healthcare Seminar 2022 and at Kapital Partner

January 18, 2022

Regulatory

Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær has been invited to present at SEB Nordic Healthcare Seminar 2022 which will take place 18 January 2022. Furthermore, Curasight will present a Deep Dive event in Head and Neck cancer at Kapital Partner, 20 January 2022.

The presentation at Kapital Partner will be webcasted live 15:00 - 16:00 (CET), Thursday 20 January 2022.

For more information – please click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Downloads

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel theranostic platform with Positron Emissions Tomography (PET) imaging  Radionuclide Therapy targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis, risk stratification and therapy in multiple cancer types.